Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.33 |
| ▸ | TDO2 | P48775 | 3/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024989 | 0.87 | PRKAG1 (0.54) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL45039 | 0.82 | PRKAG1 (0.75) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL2740539 | 0.81 | PRKAG1 (0.51) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL15752175 | 0.80 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL45770 | 0.80 | PRKAG1 (0.61) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL11025261 | 0.72 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL11026040 | 0.72 | PRKAG1 (0.44) | PRKAG1PRKAA1PRKAB1IDO1TDO2 | |
| SCHEMBL44985 | 0.72 | PRKAG1 (0.53) | PRKAG1PRKAA1PRKAB1TP53MDM2 | |
| SCHEMBL15751942 | 0.72 | PRKAG1 (0.49) | PRKAG1PRKAA1PRKAB1TP53MDM2 | |
| SCHEMBL11025262 | 0.68 | PRKAG1 (0.69) | PRKAG1PRKAA1PRKAB1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588458-B1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-8592594-B2 | Tetrahydro-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2588458-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2012001020-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | PRKAG1 3/4885PRKAA1 5/4885PRKAB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.